53 completed, 35 recruiting, 33 unknown, 10 not yet recruiting. 153 Phase 3, 23 Phase 2.
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primary Radiotherapy In MEtastatic Lung Cancer Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 3 | Recruiting | Trans Tasman Radiation Oncology Group | 420 | 2026-10-30 | 2026-10-23 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation DN022150, Chemotherapy - Pancreatic Cancer | Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 360 | 2026-09-01 | 2026-07-08 |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-26 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, Chemotherapy - Locally Advanced or Metastatic Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 356 | 2026-05-01 | 2026-04-30 |
| A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy - Locally Advanced Resectable Rectal Cancer | Phase 2 / Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 165 | 2026-03-23 | 2026-05-05 |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer PF-08634404, Bevacizumab, Chemotherapy - Intestinal Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Recruiting | Pfizer | 800 | 2025-12-11 | 2026-10-08 |
| Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer PF-08634404, Atezolizumab, Chemotherapy - Small Cell Lung Cancer (SCLC) | Phase 2 / Phase 3 | Recruiting | Pfizer | 550 | 2025-12-09 | 2026-10-08 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting Trastuzumab Deruxtecan, Chemotherapy - Endometrial Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 710 | 2025-09-30 | 2026-10-27 |
| An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II Prospidelong, chemotherapy - Gastric Cancer With Peritoneal Dissemination | Phase 2 / Phase 3 | Recruiting | Research Institute for Physical Chemical Problems of the Belarusian State University | 120 | 2025-06-20 | 2025-06-22 |
| Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer Chemotherapy, CDK4/6 Inhibitor, Endocrine therapy - Breast Cancer, Adjuvant Therapy | Phase 3 | Not yet recruiting | Fudan University | 1244 | 2025-06-15 | 2025-06-05 |
| SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer SHR-A1811, Chemotherapy - Ovarian Cancer | Phase 3 | Not yet recruiting | Tongji Hospital | 300 | 2025-06-01 | 2025-05-25 |
| SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy - Colorectal Cancer, Liver Metastases | Phase 3 | Recruiting | Jun Huang | 24 | 2025-04-10 | 2026-06-30 |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 726 | 2025-02-27 | 2026-08-10 |
| Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy - Locally Advanced Rectal Cancer (LARC), Immunotherapy | Phase 3 | Recruiting | West China Hospital | 184 | 2024-11-19 | 2025-06-13 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Quizartinib, Placebo, Chemotherapy - Leukemia | Phase 3 | Active not recruiting | Daiichi Sankyo | 700 | 2024-11-19 | 2026-07-02 |
| Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study Stereotactic body radiotherapy (SBRT), Tislelizumab, Chemotherapy - Lung Cancer (NSCLC) | Phase 3 | Recruiting | Yang Hong | 360 | 2024-10-15 | 2025-05-29 |
| A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer 9MW2821, Chemotherapy - Cervical Cancer | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 420 | 2024-09-10 | 2024-11-22 |
Showing 20 of 153. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (18) · Breast Neoplasms (16) · Ovarian Neoplasms (12) · Stomach Neoplasms (12) · Lung Neoplasms (10) · Colorectal Neoplasms (9) · Nasopharyngeal Carcinoma (7) · Esophageal Squamous Cell Carcinoma (6) · Fallopian Tube Neoplasms (5) · Neoplasm Metastasis (5) · Rectal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Uterine Cervical Neoplasms (4) · Adenocarcinoma Of Esophagus (3) · Carcinoma, Ovarian Epithelial (3)
Sun Yat-sen University (11) · Fudan University (8) · Daiichi Sankyo (4) · Hoffmann-La Roche (4) · Cordgenics, LLC (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Mabwell (Shanghai) Bioscience Co., Ltd. (3) · Peking Union Medical College Hospital (3) · Pfizer (3) · Radiation Therapy Oncology Group (3) · UNICANCER (3) · Assistance Publique - Hôpitaux de Paris (2) · Betta Pharmaceuticals Co., Ltd. (2) · Bristol-Myers Squibb (2) · David Palma (2)
China (57) · United States (40) · France (35) · Italy (30) · Germany (24) · Spain (24) · Canada (21) · United Kingdom (21) · Australia (19) · Belgium (19) · Switzerland (19) · South Korea (17) · Taiwan (17) · Austria (16) · Japan (15)
Chong Zhao, MD PhD (2) · Guoqiang Kong, MD (2) · Jing Ren, MD (2) · Rui-hua Xu, MD.,PhD. (2) · Xiaozhi Yuan, MD (2) · Alexander Zweibach, MD, PhD (1) · Andrea di Cataldo (1) · Ans Baeyes, PhD (1) · Antonio Braga, MD, PhD (1)
PMID 40288679, PMID 11560968, PMID 11870157, PMID 12525193, PMID 14645636, PMID 15128893, PMID 15534360, PMID 15936546, PMID 15961764, PMID 17404369, PMID 18248979, PMID 18650162, PMID 18784962, PMID 18955565, PMID 19652624, PMID 20888993, PMID 21300466, PMID 21673875, PMID 22663011, PMID 22726581, PMID 22749632, PMID 22772951, PMID 23168366, PMID 23852309, PMID 23916716, PMID 24439313, PMID 24485296, PMID 24504441, PMID 24888818, PMID 25273342, PMID 25679310, PMID 26105600, PMID 26159065, PMID 26163093, PMID 26275735, PMID 26446943, PMID 27172483, PMID 27323753, PMID 27502725, PMID 27959700, PMID 28945850, PMID 29443653, PMID 29522361, PMID 29654023, PMID 29697876, PMID 29733770, PMID 29739356, PMID 29859851, PMID 30059262, PMID 30690294
2017 (5), 2023 (3), 2025 (3), 2005 (2), 2016 (2), 2009 (1), 2014 (1), 2015 (1), 2018 (1), P30CA036727 (1), U10CA021661 (1), U10CA031946 (1), U10CA032102 (1), U10CA180820 (1), U10CA180830 (1)